Hubungan Antara Telogen Effluvium Dengan Pasien Paska Infeksi Covid-19 Di Rumah Sakit Umum Muhammadiyah Kota Metro Lampung

Nita Andrini, Ifadatul Fatihin

Abstract


Introduction: Covid-19 is a new corona virus that has now spread to human life, more specifically, it was first detected in Wuhan in China and has now reached 196 affected countries. Coronavirus disease 2019 is a disease caused by a virus from the Coronaviridae family called SevereAcuteRespiratory Syndrome Coronavirus-2. The Covid-19 pandemic has caused a profound psychological impact on society as a whole and a long-term sequelae of the disease. Excessive hair loss after Covid-19 can occur in patients and may affect their mental health. The hair cycle is highly susceptible to endogenous and exogenous stimuli, including febrile states and emotional stress, which persist in this era of pandemicsTelogen effluvium is a non-inflammatory disease characterized by diffuse loss of telogen hair, caused by disruption of the hair cycle leading to increased and synchronized telogen release. Methods: This research used a descriptive observational research design with cross-sectional method, which carried out for 1 month, at Muhammadiyah General Hospital Metro City, Lampung. The target population in this study were telogen effluvium sufferers with post-Covid-19 period July 2020 to May 2021, with the sampling technique used was total sampling from medical record data. Results:Based on the Chi Square test, the Fisher's Exact Test Sig value was obtained. (2-sides) is 0.001 (P<0.05) which means that there is a significant relationship between the two variables. Decision: There is a relationship between telogen effluvium in post-Covid-19 infection patients at Muhammadiyah General Hospital Metro City, Lampung.

 



Keywords


Covid-19; Telogen Effluvium

Full Text:

PDF

References


Ahmed A, Salam B, Mohammad M, Akgül A, H. A. Khoshnaw S. Analysis coronavirus disease (COVID-19) model using numerical approaches and logistic model. AIMS Bioeng. 2020;7(3):130-146.

Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733.

Güner R, Hasanoğlu İ, Aktaş F. Covid-19: Prevention and control measures in community. Turkish J Med Sci. 2020;50(SI-1):571-577.

Prateek B, Doolan C, Silva C da, Chughtai AA, Bourouiba L, MacIntyre RC. Airborne or droplet precautions for health workers treating COVID-19? J Infect Dis. 2020;189:1-4.

WHO. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. 2021 [cited 2021 Jun 21]. Available from: https://covid19.who.int/.

Informasi Covid 19 Pemerintah Provinsi Lampung. Diunduh dari : https://covid19.lampungprov.go.id

Saeed W, Hussain I, Altaf F. Telogen effluvium: Long term Covid-19 symptom. J Pakistan Assoc Dermatologists. 2020;30(4):695-698.

Roda Â, Oliveira-Soares R. Acute Telogen Effluvium in Patients Recently Infected with SARS-CoV-2. J Port Soc Dermatology Venereol. 2021;79(1):21-25.

Stephani Y, Putri EA, Irsan A. Tingkat Pengetahuan , sikap dan Perilaku terhadap Kerontokan Rambut dengan Pemakaian Jilbab pada Mahasiswi FK UNTAN. J

Cerebellum. 2018;4(2):1067-1078. https://jurnal.untan.ac.id/index.php/jfk/article/view/42055

Liyanage D, Sinclair R. Telogen effluvium. Cosmetics. 2016;3(2).

Nykolaichuk K, Kuhta О, Senchuk L. Post Covid-19 Telogen Effluvium. What Is the Reason? InterConf. Published online 2021:302-306.

Lv S, Wang L, Zou X, et al. A case of acute telogen effluvium after SARS- CoV-2 infection. Clin Cosmet Investig Dermatol. 2021;14:385-387.

Babaei K, Kavoussi H, Rezaei M, Kavoussi R. Characteristics of telogen effluvium in COVID-19 in western Iran (2020). An Bras Dermatol. 2021;96(6):688-692

Olds H, Liu J, Luk K, Lim HW, Ozog D, Rambhatla P V. Telogen effluvium associated with COVID-19 infection. Dermatol Ther. 2021;34(2):2-5.

Jose RJ, Manuel A. COVID-19 cytokine storm: the interplay between inflammation and coagulation. Lancet Respir Med. 2020;8(6):e46-e47. doi:10.1016/S2213-2600(20)30216-2

Mieczkowska, K., Deutsch, A., Borok, J., Guzman, A. K., Fruchter, R., Patel, P., Wind, O., McLellan, B. N., Mann, R. E., & Halverstam, C. P. (2021). Telogen effluvium: a sequela of COVID-19. International Journal of Dermatology, 60(1), 122–124. https://doi.org/10.1111/ijd.15313

Rizzetto G, Diotallevi F, Campanati A, et al. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience. Dermatol Ther. 2021;34(1):1-6.

Shome D, Kapoor R, Surana M, Vadera S, Shah R. Efficacy of QR678 Neo® hair growth factor formulation for the treatment of hair loss in Covid-19-induced persistent Telogen Effluvium-A prospective, clinical, single-blind study. J Cosmet Dermatol. 2022 Jan;21(1):16–23.

Kutlu Ö, Metin A. Relative changes in the pattern of diseases presenting in dermatology outpatient clinic in the era of the COVID-19 pandemic. Der- matol Ther. 2020;33:e14096.

Cline A, Kazemi A, Moy J, Safai B, Marmon S. A surge in the incidence of Telogen effluvium in minority predominant communities heavily impacted by COVID‐19. J Am Acad Dermatol. 2020;4(3):773‐775.

Sattur, S. S., & Sattur IS (2021). COVID-19 Infection: Impact on Hair. Indian journal of plastic surgery : official publication of the Association of Plastic Surgeons of India. 2021:54(4), 521–526.

Seyfi, S., Alijanpour, R., Aryanian, Z., Ezoji, K., & Mahmoudi, M. (2022). Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity. May, 631–634.

Aksoy, H., Yıldırım, U. M., Ergen, P., & Gürel, M. S. (2021). COVID-19 induced telogen effluvium. Dermatologic Therapy, 34(6), 2–6.




DOI: https://doi.org/10.30596/amj.v7i1.16877

DOI (PDF): https://doi.org/10.30596/amj.v7i1.16877.g10792

Refbacks

  • There are currently no refbacks.


Jurnal Kedokteran Anatomica/ Anatomica Medical Journal (AMJ)

Fakultas Kedokteran
Universitas Muhammadiyah Sumatera Utara, Indonesia
Kampus 1 Lantai II Laboratorium Anatomi
Jl. Gedung Arca No 53 Medan-Sumatera Utara, Indonesia.
E-mail: amj_fk@umsu.ac.id || Editorial Contact: 081375150018

Creative Commons License

This work is licensed under aCreative Commons Attribution-ShareAlike 4.0 International License.